Cardiovascular Disease, Diabetes Mellitus
Conditions
Keywords
Pragmatic randomized controlled trial, Cardiovascular risk reduction, Knowledge translation, Clinical practice guidelines, Administrative databases
Brief summary
Diabetes is a common and serious chronic disease. However, there is a large gap between the level of care that people should receive (based on research and guidelines) and the level of care they actually receive. With the release of their 2008 Clinical Practice Guidelines, the Canadian Diabetes Association has a strategy to improve heart disease screening and treatment for people with diabetes. This study will evaluate whether the strategy works. The focus of the strategy was to give all family physicians in Canada a Toolkit in June 2009 to help them delivery better care for their diabetic patients. In Ontario, only half of doctors received this Toolkit. We will compare the quality of care received by diabetic patients whose doctors received this Toolkit versus those who doctors did not.
Detailed description
A cardiovascular disease Toolkit was developed by the Canadian Diabetes Association and mailed to family physician with the Spring/Summer 2009 edition of the newsletter, Canadian Diabetes. The Toolkit was packaged in a brightly-coloured box with Canadian Diabetes Association branding, and contained: 1) an introductory letter from the Chair of the practice guidelines' Dissemination and Implementation Committee; 2) an eight page summary of selected sections of the practice guidelines targeted towards primary care physicians; 3) a four page synopsis of the key guideline elements pertaining to cardiovascular disease risk; 4) a small double-sided laminated card with a simplified algorithm for cardiovascular risk assessment, vascular protection strategies and screening for cardiovascular disease; and 5) a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool and a list of recommended risk reduction strategies.
Interventions
Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed with the May 2010 issue of the newsletter.
Sponsors
Study design
Eligibility
Inclusion criteria
* Alive on 1 July 2009 with prevalent diabetes
Exclusion criteria
* Age \<= 39 * Residing in long-term care Secondary Analysis: * Analysis will be repeated using all people alive on 1 July 2009 without prevalent diabetes using the same
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Death or non-fatal myocardial infarction | Up to 10 months |
Secondary
| Measure | Time frame |
|---|---|
| Death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for unstable angina or transient ischemic attack | Up to 10 months |
| Death | Up to 10 months |
| Hospitalization for myocardial infarction | Up to 10 months |
| Hospitalization for myocardial infarction or unstable angina | Up to 10 months |
| Hospitalization for stroke | Up to 10 months |
| Hospitalization for stroke or transient ischemic attack | Up to 10 months |
| Electrocardiogram | Up to 10 months |
| Cardiac stress test or nuclear imaging | Up to 10 months |
| Coronary angiography | Up to 10 months |
| Death, non-fatal myocardial infarction or non-fatal stroke | Up to 10 months |
| Ambulatory cardiology or internal medicine visit | Up to 10 months |
| Prescription for angiotensin converting enzyme inhibitor or angiotensin receptor blocker | Up to 10 months |
| Prescription for at least one class of antihypertensive agent | Up to 10 months |
| Prescription for at least two classes of antihypertensive agents | Up to 10 months |
| Prescription for at least three classes of antihypertensive agents | Up to 10 months |
| Prescription for statin | Up to 10 months |
| Prescription for any glucose-lowering drug | Up to 10 months |
| Prescription for insulin | Up to 10 months |
| Prescription for nitrate | Up to 10 months |
| Coronary revascularization procedure | Up to 10 months |
Countries
Canada